Home > Insider Trading > Filing (0001567619-21-022541)

Filing Details

Accession Number:: 0001567619-21-022541
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-12-27 20:09:36
Reporting Period:: 2021-12-22

Accepted Time:: 2021-12-27 20:09:36
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1630627	Treace Medical Concepts Inc.	TMCI	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1185191	T James Treace	C/O Treace Medical Concepts, Inc. 203 Fort Wade Road, Suite 150 Ponte Vedra FL 32081		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-12-22	23,390	$16.28	20,612	No	4	S	Indirect	By J&A Group LLC
Common Stock	Disposition	2021-12-23	12,610	$16.90	8,002	No	4	S	Indirect	By J&A Group LLC
Common Stock	Disposition	2021-12-27	6,437	$17.46	1,565	No	4	S	Indirect	By J&A Group LLC

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By J&A Group LLC
No	4	S	Indirect	By J&A Group LLC
No	4	S	Indirect	By J&A Group LLC

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,006,183	Indirect	By spouse
Common Stock	1,461,441	Direct

Footnotes

Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
James T. Treace and his spouse are managing members of J&A Group, LLC, a Florida limited liability company.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.59 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.50 to $17.29 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.25 to $17.615 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.